Zacks: Brokerages Anticipate VBI Vaccines Inc. (NASDAQ:VBIV) Will Announce Earnings of -$0.07 Per Share

Brokerages predict that VBI Vaccines Inc. (NASDAQ:VBIV) will announce ($0.07) earnings per share for the current quarter, according to Zacks. Three analysts have issued estimates for VBI Vaccines’ earnings, with estimates ranging from ($0.09) to ($0.05). VBI Vaccines reported earnings of ($0.05) per share during the same quarter last year, which would indicate a negative year over year growth rate of 40%. The company is expected to issue its next earnings results on Wednesday, May 5th.

According to Zacks, analysts expect that VBI Vaccines will report full year earnings of ($0.27) per share for the current fiscal year, with EPS estimates ranging from ($0.33) to ($0.24). For the next year, analysts expect that the firm will post earnings of ($0.13) per share, with EPS estimates ranging from ($0.29) to $0.05. Zacks’ EPS calculations are an average based on a survey of analysts that cover VBI Vaccines.

VBI Vaccines (NASDAQ:VBIV) last issued its quarterly earnings results on Monday, March 1st. The biopharmaceutical company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). The firm had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.44 million. VBI Vaccines had a negative return on equity of 36.69% and a negative net margin of 2,837.73%.

A number of research analysts recently commented on VBIV shares. Zacks Investment Research downgraded VBI Vaccines from a “hold” rating to a “sell” rating in a report on Saturday, March 6th. Jefferies Financial Group initiated coverage on VBI Vaccines in a report on Thursday, February 25th. They set a “buy” rating and a $7.00 target price on the stock. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $5.90.

Shares of VBIV opened at $2.94 on Wednesday. The company has a market capitalization of $747.33 million, a P/E ratio of -17.29 and a beta of 2.14. VBI Vaccines has a one year low of $1.18 and a one year high of $6.93. The company has a debt-to-equity ratio of 0.10, a quick ratio of 8.95 and a current ratio of 9.06. The stock has a 50-day moving average price of $3.06 and a 200 day moving average price of $3.09.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Grimes & Company Inc. lifted its holdings in shares of VBI Vaccines by 2.6% in the 4th quarter. Grimes & Company Inc. now owns 140,919 shares of the biopharmaceutical company’s stock worth $388,000 after purchasing an additional 3,627 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of VBI Vaccines by 9.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 106,160 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 8,796 shares during the last quarter. DCF Advisers LLC lifted its holdings in shares of VBI Vaccines by 35.8% in the 4th quarter. DCF Advisers LLC now owns 36,000 shares of the biopharmaceutical company’s stock worth $99,000 after purchasing an additional 9,500 shares during the last quarter. Sax Wealth Advisors LLC bought a new stake in shares of VBI Vaccines in the 4th quarter worth approximately $28,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of VBI Vaccines by 10.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 107,368 shares of the biopharmaceutical company’s stock worth $295,000 after purchasing an additional 10,200 shares during the last quarter. 52.13% of the stock is currently owned by institutional investors and hedge funds.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

Further Reading: Understanding the different types of bonds

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.